TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19929644
Drug: Diaphragm and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragm and lubricant gel intervention
Study: 15679256
Drug: Targeted drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted drugs in combination with ionizing radiation
Study: 10678543
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor ramipril (5 mg/day for 3 weeks)
Study: 10678543
Drug: AT1B losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1B losartan (50 mg/day for 3 weeks)
Study: 10678543
Drug: Control L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control L-arginine infusion
Study: 10678543
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor ramipril and AT1B losartan
Study: 9549634
Drug: Enalapril/Diltiazem ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril/Diltiazem ER with other agents (n = 79)
Study: 3484691
Drug: Digoxin, 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin, 0.375 mg/day, loaded with doubled doses on days 1 and 2, for 14 days.
Study: 3484691
Drug: Bepridil, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil, 300 mg/day, loaded with 900 mg on day 8.
Study: 3484691
Drug: Concurrent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent dosing of digoxin and bepridil.
Study: 3484691
Drug: Concurrent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent dosing of both drugs.
Study: 26092233
Drug: lipegfilgrastim 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipegfilgrastim 6 mg
Study: 19896200
Drug: Re-ChORD (integrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-ChORD (integrative treatment program including medication management, interpersonal psychotherapy, and occupational therapy)
Study: 8918674
Drug: Routine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine administration of rG‐CSF on the 6th day after BEP chemotherapy (group A)
Study: 8918674
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of rG‐CSF after granulocytopenia of 1,500/mm3 had developed (group B)
Study: 8918674
Drug: BEP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEP chemotherapy
Study: 1747882
Drug: Fluoride toothpaste
Normalized name: sodium fluoride Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride toothpaste with sodium monofluorophosphate, calcium glycerophosphate supplement, and calcium carbonate abrasive
Study: 1747882
Drug: Fluoride toothpaste
Normalized name: sodium fluoride Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride toothpaste with sodium monofluorophosphate and sodium fluoride, calcium glycerophosphate supplement, and calcium carbonate abrasive
Study: 27909081
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) monotherapy
Study: 28763316
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (5 mg/kg) coadministered with neostigmine (25 μg/kg) and atropine (15 μg/kg)
Study: 28763316
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline coadministered with neostigmine (25 μg/kg) and atropine (15 μg/kg)
Study: 23468553
Drug: Maternal lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal lipid-based nutrient supplements (LNS) during lactation
Study: 16490808
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) 20 mg for 7 days with CyA 100 mg coadministered on day 7
Study: 16490808
Drug: CyA 100
Normalized name: Sangcya 100mg/ml Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA 100 mg alone
Study: 7225165
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg tid for 4 weeks
Study: 7225165
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg tid for 9 weeks
Study: 7225165
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg tid for 9 weeks in 10 subjects with lipoprotein cholesterol fractionation
Study: 30778571
Drug: EOD1 (Essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOD1 (Essential oil blends and Vitamin D3; 50 μg 25‐OH‐D3/kg diet, 15 mg CRINA Poultry/kg diet)
Study: 30778571
Drug: EOD2 (Essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOD2 (Essential oil blends and Vitamin D3; 69 μg 25‐OH‐D3/kg diet, 30 mg CRINA Poultry/kg diet)
Study: 30778571
Drug: EOD3 (Essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOD3 (Essential oil blends and Vitamin D3; 138 μg 25‐OH‐D3/kg diet, 50 mg CRINA Poultry/kg diet)
Study: 29851824
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of rocuronium intravenously (group L)
Study: 29851824
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg of rocuronium (group C)
Study: 24128379
Drug: Opioid substitution
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid substitution therapy (OST)
Study: 22292061
Drug: Intervention by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention by clinical pharmacists including answering questions of physicians and nurses, giving advice on treating patients, checking prescriptions and patient counseling at discharge.
Study: 17516484
Drug: Entacapone (ENT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (ENT), 3 to 5 times daily
Study: 17516484
Drug: Cabergoline (CBG),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (CBG), titrated to a maximum of 6 mg/d
Study: 12390384
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg intravenously twice daily followed by oral ranitidine 150 mg twice daily for 5 years
Study: 10090428
Drug: Sparfloxacin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 400 mg loading dose on day 1, followed by 200 mg once daily for 10 days
Study: 31153360
Drug: Dexmedetomidine 0
Normalized name: dexmedetomidine 0.12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0 mcg/kg (group 1)
Study: 31153360
Drug: Dexmedetomidine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.3 mcg/kg (group 2)
Study: 31153360
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 mcg/kg (group 3)
Study: 31153360
Drug: Dexmedetomidine 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.9 mcg/kg (group 4)
Study: 24448227
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg daily for 24 months
Study: 24448227
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for 24 months
Study: 17263650
Drug: TPV/r 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r 500 mg/100 mg
Study: 17263650
Drug: TPV/r 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r 500 mg/200 mg
Study: 17263650
Drug: TPV/r 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r 750 mg/200 mg
Study: 12473477
Drug: Ampicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (1 g)
Study: 12473477
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mL sterile water)
Study: 9666830
Drug: 5 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 times weekly narrow-band TL-01 UVB phototherapy
Study: 9666830
Drug: 3 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times weekly narrow-band TL-01 UVB phototherapy
Study: 7648653
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg TID)
Study: 2667654
Drug: Adjuvant cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant cytotoxic chemotherapy (76 patients)
Study: 2667654
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic adjuvant treatment (93 patients)
Study: 2667654
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy (oral cyclophosphamide and intravenous methotrexate and 5‐fluorouracil) for 12 cycles over one year
Study: 908220
Drug: fenoterol 400
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol 400 μg
Study: 908220
Drug: fenoterol 200
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol 200 μg
Study: 908220
Drug: fenoterol 100
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenoterol 100 μg
Study: 908220
Drug: isoproterenol 150
Normalized name: anhydrous calcium iodide-isoproterenol 150 mg-3 mg/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: isoproterenol 150 μg
Study: 908220
Drug: All drug
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drug regimens
Study: 29728338
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with Magnesium (Mg)
Study: 29728338
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment with maltose
Study: 28210090
Drug: Stellate ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate ganglion block treatment (experimental group, n = 90)
Study: 28210090
Drug: Oral sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfasalazine treatment (control group, n = 30)
Study: 18505226
Drug: Clearfil SE
Normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clearfil SE Bond with 37% phosphoric acid gel
Study: 18505226
Drug: Xeno III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xeno III with 37% phosphoric acid gel
Study: 11142927
Drug: Formica rufa
Normalized name: Formica Rufa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formica rufa D6 (1 ml) + autologous blood (0.5 ml)
Study: 11142927
Drug: Placebo (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.5 ml NaCl intramuscular)
Study: 1510000
Drug: Flecainide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (2 mg/kg body weight in 10 minutes)
Study: 1510000
Drug: Propafenone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (2 mg/kg body weight in 10 minutes)
Study: 1510000
Drug: Verapamil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (10 mg in 1 minute)
Study: 29776916
Drug: NIR light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR light therapy (940 nm) to acupoints in the legs and feet, 12 sessions during hemodialysis three times a week
Study: 29776916
Drug: NIR light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR light therapy (940 nm) to acupoints in the legs and feet
Study: 25640007
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day SCSE for 14 days
Study: 24285458
Drug: Specialized physiotherapy
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized physiotherapy methods (6 additional massage treatments, 30 minutes each, over a few days)
Study: 24285458
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard pharmacological treatment and basic physiotherapy)
Study: 21034249
Drug: Phage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phage treatment (3×10^9 plaque forming units) administered via oral gavage at 24 and 48 hours
Study: 21034249
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no phage treatment)
Study: 21034249
Drug: Phage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phage treatment
Study: 16572330
Drug: 1.0% water-soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% water-soluble reduced chitosan (5.0 g/l)
Study: 12573306
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (EV) 2 mg
Study: 7515260
Drug: Aprotinin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (0.5 x 10(6) KIU intravenous bolus after induction and 10(6) KIU into the pump prime)
Study: 2885022
Drug: Adimolol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adimolol (600 mg)
Study: 26204987
Drug: Carraguard microbicide
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carraguard microbicide gel
Study: 26204987
Drug: High adherence
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High adherence (gel used in >=85% of sex acts)
Study: 25277886
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein concentrate (WPC) 65 g dissolved in 500 mL water 30 minutes before lunch
Study: 25277886
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI) 60 g dissolved in 500 mL water 30 minutes before lunch
Study: 20427390
Drug: LAL: levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAL: levofloxacin (750 mg once a day), amoxicillin (1000 mg twice a day), lansoprazole (30 mg twice a day) for 7 days
Study: 20427390
Drug: CAL: clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL: clarithromycin (500 mg twice a day), amoxicillin (1000 mg twice a day), lansoprazole (30 mg twice a day) for 7 days
Study: 20427390
Drug: LAL as
Normalized name: Lathanol LAL
DrugBank: Sodium lauryl sulfoacetate (DB13157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAL as second-line treatment
Study: 20427390
Drug: CAL as
Normalized name: Cal Gest
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL as second-line treatment
Study: 26051846
Drug: Phonophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis with dexketoprofen (50 mg/session) (n=33)
Study: 26051846
Drug: Iontophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoresis with dexketoprofen (50 mg/session) (n=34)
Study: 22554205
Drug: Glycerin 1%
Normalized name: GLYCERIN 1% OPH SOLN SPRAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin 1% formulated with PLL-g-PEG
Study: 20404743
Drug: Bedtime dosing
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime dosing of candesartan (with or without diuretic)
Study: 20404743
Drug: Awakening dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Awakening dosing of candesartan (with or without diuretic)
Study: 20404743
Drug: Bedtime dosing
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime dosing of candesartan in morning hypertension group
Study: 20404743
Drug: Awakening dosing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Awakening dosing of candesartan in morning hypertension group
Study: 12394700
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg daily for 2 weeks before surgery
Study: 27104933
Drug: Everolimus combined
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus combined with cyclosporine A (CsA) and steroids
Study: 17299100
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment program including cognitive behavioral therapy, interpersonal therapy, nutritional counseling, and supervised walking exercise (15 sessions).
Study: 15805342
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2 and 4 mg)
Study: 15805342
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch and gum
Study: 15805342
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (patch, gum, placebo)
Study: 15805342
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch therapy with cognitive-behavioral therapy
Study: 30777645
Drug: Intervention (We
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (We Immunize Program with practical strategies training and monthly telephonic expert feedback)
Study: 26467301
Drug: Chlorhexidine-containing brush-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-containing brush-on gel (0.2% chlorhexidine digluconate) used once daily for 12 weeks
Study: 16778332
Drug: Imidapril 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 2.5 mg once daily for 6 months
Study: 14759425
Drug: Intravenous methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylene blue (1.5 mg/Kg)
Study: 11718638
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (NTG) patch (5 mg for 3 days)
Study: 2824708
Drug: Late intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late intensification chemotherapy (high-dose chemotherapy)
Study: 30006361
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of the β‐blocker propranolol
Study: 30006361
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of amisulpride
Study: 16160693
Drug: Chemotherapy (beneficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (beneficial effect group, n = 245)
Study: 16160693
Drug: Chemotherapy (progressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (progressive disease group, n = 58)
Study: 16160693
Drug: Chemotherapy (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (group with 0-1 adverse events)
Study: 16160693
Drug: Chemotherapy (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (group with 2-5 adverse events)
Study: 16160693
Drug: Chemotherapy (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (group with >=6 adverse events)
Study: 12831816
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n=199) with lifestyle modification and pharmacological treatments individualized by a geriatrician
Study: 8880109
Drug: Ultrasonically-nebulized distilled
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonically-nebulized distilled water (UNDW) - 10 min inhalation
Study: 8880109
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (HS) - stepwise inhalation of 4.5% saline for 0.5, 1, 2, 4, and 8 min
Study: 31100611
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg for 8 weeks)
Study: 30196397
Drug: MDMA (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (75 to 125 mg)
Study: 17725245
Drug: DEX 960
Normalized name: Dex
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DEX 960 mg
Study: 17725245
Drug: DEX 1,920
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 1,920 mg
Study: 16038522
Drug: Amoxicillin/sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/sulbactam
Study: 12048095
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (group I) with continuous infusion of bupivacaine 0.125% and 2mg fentanyl/ml at a dosage of 6-10 ml per hour for 5 days.
Study: 12048095
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve block (group II) with 20 ml 0.5% bupivacaine applied at the end of the operation.
Study: 7743697
Drug: Vasodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator therapy (hydralazine/isosorbide dinitrate)
Study: 26509639
Drug: Carboxymethylcellulose (CMC)
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxymethylcellulose (CMC) gel
Study: 23047822
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg intravenously at days 1 and 15, plus standard chemotherapy)
Study: 23047822
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (3 + 7)
Study: 23047822
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg intravenously at days 1 and 15, plus cytarabine 1000 mg/m(2) twice daily on days 1‐6)
Study: 17304449
Drug: Sb(v) plus
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sb(v) plus oral pentoxifylline for 30 days
Study: 17304449
Drug: Sb(v) plus
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sb(v) plus oral placebo
Study: 3281387
Drug: Adjuvant-only preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant-only preparation
Study: 5317541
Drug: Metaproterenol aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol aerosol (0.65 mg per dose, taken as required several times daily)
Study: 5317541
Drug: Metaproterenol aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol aerosol (average treatment duration of about four months)